ATR — AptarGroup, Inc.

Is ATR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Neutral As of November 17, 2026

AptarGroup, Inc. (ATR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $140.33. The rating moved from Overbought to Neutral on November 17, 2026.

AI analysis

AptarGroup combines stable, diversified end-market exposure with a growing presence in pharma/device dispensing, positioning it to capture incremental demand from specialty injectable therapies and specialty distribution channels. The business benefits from long product development cycles and strong OEM relationships that support recurring revenue and some pricing flexibility. Near-term results will depend on raw-material cost pass-through, execution on manufacturing efficiency, and retention of large customers. Key upside catalysts include accelerating adoption of advanced drug-delivery systems and continued demand in personal-care and specialty pharma channels; downside scenarios center on margin compression from input-cost inflation, supply disruptions, or loss of significant customer volumes.

Key factors

  • Exposure to pharmaceutical and specialty drug delivery systems benefiting from secular growth in injectable and specialty therapies
  • Diversified end markets (beauty, personal care, food & beverage, healthcare) provide revenue stability and offset cyclicality in any single sector
  • Strong customer relationships and long product development cycles create barriers to entry and some pricing power for customized dispensing solutions
  • Operational scale and global manufacturing footprint support cost efficiency and ability to serve large multinational customers
  • Sector tailwinds: increased uptake of chronic injectable therapies and specialty distribution channels can raise demand for advanced dispensing and containment solutions

Risks

  • Raw material and energy cost inflation that could compress gross margins if not fully passed through to customers
  • Supply chain disruptions or manufacturing quality issues that could interrupt deliveries to large pharma customers or trigger remediation costs
  • Customer concentration: reliance on a handful of large CPG and pharma customers could amplify revenue volatility if contracts are lost or volumes decline
  • Foreign exchange exposure and geopolitical events affecting international sales and margins
  • Competitive pressure from alternative delivery-system providers and potential commoditization of some components
  • Slower consumer spending or macro weakness that reduces demand in non-healthcare end markets

See today's live rating, score and targets

Members see the live hourly rating for ATR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.